Filing identity and business context
Important identity mismatch: The supplied filing is TradeUP Acquisition Corp.’s Form 10-Q for the quarter ended June 30, 2022, not an Estrella Immunopharma, Inc. filing. Verify the issuer before relying on this summary.
TradeUP was a blank-check company seeking a business combination. As of the filing, it had not selected a target, had not commenced operating activities, and had no operating revenue. The filing was signed August 8, 2022; financial statements are unaudited.
Financial results and position
| Metric | Three months ended June 30, 2022 | Six months ended June 30, 2022 |
|---|---|---|
| Operating revenue | None | None |
| Net loss | $359,586 | $500,838 |
| Trust-account dividend income | $64,179 | $67,867 |
| Operating cash flow | Net cash used: $390,587 |
Second-quarter costs included $399,765 of formation and operating costs and $24,000 of franchise taxes. For the six-month period, those costs were $520,505 and $48,200, respectively. Profit margins are not meaningful because the company had no operating revenue.
At June 30, 2022, total assets were $45.38 million, including $45.26 million in the trust account and $88,281 of cash outside the trust. Total liabilities were $1.71 million, including $1.55 million of deferred business-combination marketing fees; current liabilities were $154,647. Redeemable shares were classified as temporary equity at $45.19 million. Stockholders’ deficit was $1.51 million. The filing reports no long-term debt or contractual lease obligations at quarter-end.
Changes versus the prior comparable period
Net loss increased from $3,555 in the second quarter of 2021 to $359,586 in the second quarter of 2022. For the six months ended June 30, 2022, net loss was $500,838, compared with $4,374 from inception through June 30, 2021; the latter is not a full six-month comparison because the company was incorporated in January 2021. Trust-account income rose to $67,867 for the 2022 six-month period from $4 for the 2021 inception-to-date period. Cash outside the trust declined from $478,868 at December 31, 2021 to $88,281 at June 30, 2022.
Outlook, risks and unusual items
- The company had until January 19, 2023 to complete a business combination; otherwise it was required to wind up and redeem public shares under the stated terms. Warrants would expire worthless if no combination was completed.
- Management expected to use outside-trust funds for the search and transaction process and believed working capital and borrowing capacity would meet needs through a combination or one year from filing. It cautioned that actual search and transaction costs could exceed available funds and additional financing might be needed.
- On July 25, 2022, the company issued two unsecured, non-interest-bearing related-party notes totaling $498,600: $204,000 to an entity controlled by a co-CEO/director and $294,600 to a founder. They were for general working capital, due at the business combination or term expiry, and convertible at the payees’ option into shares at $10 per share.
- The company disclosed that disclosure controls were not effective due to a material weakness in accounting for complex equity instruments associated with the IPO and a restatement related to redeemable-share classification. Management described planned training and increased consultation with accounting professionals; it provided no assurance that further control changes would not be needed.
- Management said COVID-19 could adversely affect the company’s financial position, results, or target search, but the impact was not readily determinable. No material legal proceedings were reported, and the company said there were no material changes to prospectus risk factors.
- The deferred $1,550,500 business-combination fee is payable to underwriter representatives upon completion of a combination. The sponsor’s trust-account indemnity is subject to stated limitations and exceptions.
Most important facts to verify
- Confirm that TradeUP Acquisition Corp., rather than Estrella Immunopharma, is the intended issuer and filing.
- Confirm whether a business combination was completed by the January 19, 2023 deadline and the resulting treatment of public shares and warrants.
- Check the drawdowns, repayment, or conversion of the $498,600 related-party notes and any later financing.
- Review subsequent filings for remediation of the disclosed material weakness and any further restatements or control findings.
- Verify the cash available outside the trust and actual transaction costs against management’s liquidity expectations.